ID   T98G
AC   CVCL_0556
SY   T 98 G; T-98G; T98 G; T98-G
DR   BTO; BTO:0001583
DR   CLO; CLO_0009236
DR   CLO; CLO_0009258
DR   CLO; CLO_0050636
DR   EFO; EFO_0002085
DR   MCCL; MCC:0000457
DR   CLDB; cl4478
DR   CLDB; cl4480
DR   CLDB; cl4481
DR   CLDB; cl4482
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1690
DR   BioSample; SAMN01821603
DR   BioSample; SAMN01821719
DR   BioSample; SAMN01821740
DR   BioSample; SAMN03473051
DR   BioSample; SAMN05292443
DR   BioSample; SAMN07710005
DR   BioSample; SAMN07710006
DR   BioSample; SAMN07710007
DR   BioSample; SAMN07710008
DR   BioSample; SAMN07710009
DR   BioSample; SAMN07710010
DR   BioSample; SAMN07710011
DR   BioSample; SAMN10988244
DR   CCLE; T98G_CENTRAL_NERVOUS_SYSTEM
DR   Cell_Model_Passport; SIDM01171
DR   CGH-DB; 154-1
DR   ChEMBL-Cells; CHEMBL3307777
DR   ChEMBL-Targets; CHEMBL614775
DR   Cosmic; 687586
DR   Cosmic; 759898
DR   Cosmic; 849847
DR   Cosmic; 850740
DR   Cosmic; 897444
DR   Cosmic; 1175821
DR   Cosmic; 1217675
DR   Cosmic; 1294953
DR   Cosmic; 1610748
DR   Cosmic; 1746960
DR   Cosmic; 2302325
DR   Cosmic; 2367552
DR   Cosmic; 2491103
DR   Cosmic; 2516040
DR   Cosmic; 2701088
DR   Cosmic-CLP; 687586
DR   DepMap; ACH-000571
DR   ECACC; 92090213
DR   GDSC; 687586
DR   GEO; GSM326205
DR   GEO; GSM887687
DR   GEO; GSM888779
DR   GEO; GSM1374954
DR   GEO; GSM1670523
DR   IARC_TP53; 2574
DR   IZSLER; BS TCL 63
DR   JCRB; IFO50303
DR   JCRB; JCRB9041
DR   KCLB; 21690
DR   LiGeA; CCLE_712
DR   LINCS_LDP; LCL-1357
DR   PharmacoDB; T98G_1562_2019
DR   PRIDE; PXD000589
DR   PRIDE; PXD002192
DR   RCB; RCB1954
DR   TKG; TKG 0471
DR   Wikidata; Q52609889
RX   PubMed=222778;
RX   PubMed=3413074;
RX   PubMed=10416987;
RX   PubMed=10560660;
RX   PubMed=11414198;
RX   PubMed=14614447;
RX   PubMed=16232199;
RX   PubMed=18445040;
RX   PubMed=19435942;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20587068;
RX   PubMed=22460905;
RX   PubMed=22570425;
RX   PubMed=25485619;
RX   PubMed=25894527;
RX   PubMed=25984343;
RX   PubMed=26496030;
RX   PubMed=27397505;
RX   PubMed=28464039;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://en.wikipedia.org/wiki/T98G
WW   https://physics.cancer.gov/docs/bioresource/brain/NCI-PBCF-CRL1690_T98G_SOP-508.pdf
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-574.html
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Doubling time: 40 hours (PubMed=25984343); ~28 hours (PBCF).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Has no IDH1 mutation (PubMed=19435942).
CC   Sequence variation: PTEN p.Leu42Arg (c.125T>G) (PubMed=10560660; PubMed=28464039).
CC   Sequence variation: TP53 p.Met237Ile (c.711G>T) (PubMed=10416987; PubMed=14614447).
CC   Omics: Cell surface proteome.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.56%; Native American=0.16%; East Asian, North=4.73%; East Asian, South=0%; South Asian=6.52%; European, North=26.22%; European, South=60.81% (PubMed=30894373).
ST   Source(s): ATCC; COG; Cosmic-CLP; ECACC; JCRB; KCLB; PubMed=22570425; PubMed=25877200; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 13
ST   D16S539: 13
ST   D18S51: 13,16
ST   D19S433: 12,13
ST   D21S11: 28,32.2
ST   D2S1338: 19,24
ST   D3S1358: 16
ST   D5S818: 10,12
ST   D7S820: 9,10
ST   D8S1179: 13,14
ST   FGA: 21,22 (COG; KCLB)
ST   FGA: 21 (PubMed=22570425; PubMed=25877200)
ST   Penta D: 10,11
ST   Penta E: 16
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 17,20
DI   NCIt; C3058; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_B368 ! T98
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 27
//
RX   PubMed=222778; DOI=10.1002/jcp.1040990107;
RA   Stein G.H.;
RT   "T98G: an anchorage-independent human tumor cell line that exhibits
RT   stationary phase G1 arrest in vitro.";
RL   J. Cell. Physiol. 99:43-54(1979).
//
RX   PubMed=3413074; DOI=10.1073/pnas.85.16.6042;
RA   Pereira-Smith O.M., Smith J.R.;
RT   "Genetic analysis of indefinite division in human cells:
RT   identification of four complementation groups.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988).
//
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
//
RX   PubMed=10560660; DOI=10.1097/00005072-199911000-00007;
RA   Schmidt E.E., Ichimura K., Goike H.M., Moshref A., Liu L.,
RA   Collins V.P.;
RT   "Mutational profile of the PTEN gene in primary human astrocytic
RT   tumors and cultivated xenografts.";
RL   J. Neuropathol. Exp. Neurol. 58:1170-1183(1999).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=14614447; DOI=10.1038/sj.onc.1207198;
RA   Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.;
RT   "CP-31398, a novel p53-stabilizing agent, induces p53-dependent and
RT   p53-independent glioma cell death.";
RL   Oncogene 22:8233-8245(2003).
//
RX   PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x;
RA   Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T.,
RA   Aoyagi M., Ohno K., Imoto I., Inazawa J.;
RT   "Overexpressed Skp2 within 5p amplification detected by array-based
RT   comparative genomic hybridization is associated with poor prognosis of
RT   glioblastomas.";
RL   Cancer Sci. 96:676-683(2005).
//
RX   PubMed=18445040; DOI=10.1111/j.1742-4658.2008.06452.x;
RA   Kikuchi Y., Kakeya T., Nakajima O., Sakai A., Ikeda K., Yamaguchi N.,
RA   Yamazaki T., Tanamoto K., Matsuda H., Sawada J., Takatori K.;
RT   "Hypoxia induces expression of a GPI-anchorless splice variant of the
RT   prion protein.";
RL   FEBS J. 275:2965-2976(2008).
//
RX   PubMed=19435942; DOI=10.1215/15228517-2009-025;
RA   Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R.,
RA   Jones D.T.W., Collins V.P.;
RT   "IDH1 mutations are present in the majority of common adult gliomas
RT   but rare in primary glioblastomas.";
RL   Neuro-oncol. 11:341-347(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20587068; DOI=10.1186/1471-2407-10-339;
RA   Nakabayashi H., Yawata T., Shimizu K.;
RT   "Anti-invasive and antiangiogenic effects of MMI-166 on malignant
RT   glioma cells.";
RL   BMC Cancer 10:339-339(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26496030; DOI=10.18632/oncotarget.6171;
RA   Patil V., Pal J., Somasundaram K.;
RT   "Elucidating the cancer-specific genetic alteration spectrum of
RT   glioblastoma derived cell lines from whole exome and RNA sequencing.";
RL   Oncotarget 6:43452-43471(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28464039; DOI=10.1371/journal.pone.0176683;
RA   Hill V.K., Kim J.-S., James C.D., Waldman T.;
RT   "Correction of PTEN mutations in glioblastoma cell lines via
RT   AAV-mediated gene editing.";
RL   PLoS ONE 12:E0176683-E0176683(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//